MUC17 Diagnostic Antibodies for Accurate Tumor Expression Profiling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is conflicting evidence in the literature regarding MUC17 as a potential target for treating various malignancies, leading to the need for diagnostic tools that can selectively identify conditions associated with MUC17 upregulation to ensure appropriate therapeutic interventions for critically ill patients.
Innovation Solution
Development of antibodies that specifically bind to MUC17, allowing for diagnostic methods to detect and quantify MUC17 expression in tissue samples, monitor disease progression, and evaluate therapeutic response, using immunohistochemistry and fluorescence activated cell sorting assays.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If therapeutic antibody constructs are used to treat malignancies, then treatment effectiveness may be improved, but inappropriate treatment may occur due to conflicting evidence about MUC17 expression patterns
Solution Approach 1:
The patent applies preliminary action by developing and providing diagnostic antibodies and detection methods that can be used before therapeutic intervention. These diagnostic tools enable clinicians to determine MUC17 expression patterns in patient samples prior to treatment, ensuring that therapeutic antibody constructs are only administered to patients who will benefit from them based on their specific MUC17 status
Solution Approach 2:
The patent uses diagnostic antibodies as an intermediary between the conflicting literature evidence and therapeutic decision-making. These diagnostic antibodies provide a direct, reliable measurement of MUC17 expression in patient samples, serving as a mediator that translates complex, conflicting research data into clear, actionable clinical information for treatment selection
2Measurement precision
If diagnostic methods are developed to detect MUC17 expression, then treatment decisions can be optimized, but device complexity and development time increase
Solution Approach 1:
The patent applies universality by designing diagnostic antibodies with standardized formats (such as ELISA, immunohistochemistry, and flow cytometry compatibility) that can be used across multiple detection platforms and clinical settings. This multi-functionality allows the same antibody reagent to serve various diagnostic purposes without requiring separate specialized tools for each application
Solution Approach 2:
The patent employs parameter changes by optimizing antibody characteristics such as affinity, specificity, and detection sensitivity to achieve high measurement precision. By carefully tuning these parameters during antibody development and validation, the patent achieves accurate MUC17 detection while maintaining compatibility with existing standard diagnostic workflows, thereby limiting the increase in operational complexity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables accurate identification of MUC17 expression in neoplastic diseases, facilitating appropriate treatment decisions and reducing the risk of inappropriate treatments in patients.
Implementation Method 1
antibodies that bind to mucin 17 (MUC17)... antibodies that specifically bind to MUC17
Data Source
AI summary
The present invention relates to antibodies that bind to human and monkey mucin 17 (MUC17). Moreover, the invention relates to a detection system comprising such antibodies. The antibodies or the detection system may be used for detecting or quantifying MUC17, for diagnosing a disease associated with MUC17, for patient stratification, monitoring disease progression, and evaluating the therapeutic response.